LeenaGandhiMD

Oncology • Boston, MA

Associate Professor, Dana-Farber Cancer Institute, Harvard Medical School

Join to view full profile

Dr. Gandhi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gandhi's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-6049

Fax+1 617-632-2630

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2008
Massachusetts General HospitalResidency, Internal Medicine, 2002 - 2004
New York University School of MedicineClass of 2002

Certifications & Licensure

MA State Medical License 2005 - 2025
NY State Medical License 2016 - 2023

Clinical Trials

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2010 Jul 28
Completed
Phase 2
Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2010 Jun 01
Completed
Phase 2
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 1
A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors Start of enrollment: 2012 Oct 01
Completed
Phase 1
AUY922 for Advanced ALK-positive NSCLC Start of enrollment: 2013 Jan 01
Completed
Phase 2
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR Start of enrollment: 2013 Jul 01
Completed
Phase 2
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy Start of enrollment: 2015 Oct 13
Active, not recruiting
Phase 1, Phase 2
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer Start of enrollment: 2018 Mar 30
Terminated
Phase 2
Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) Start of enrollment: 2017 Jan 23
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Identifying Oncology Clinical Trial Candidates Using Artificial Intelligence Predictions of Treatment Change: A Pilot Implementation Study.
Kenneth L Kehl, Tali Mazor, Pavel Trukhanov, James Lindsay, Matthew R Galvin
JCO Precision Oncology. 2024-03-01
14 citations
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
Ernest Nadal, Mansoor Saleh, Santiago Ponce Aix, Maria Ochoa-de-Olza, Sandip Pravin Patel
BMC Cancer. 2023-07-28
21 citations
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors.
H Park, G I Shapiro, X Gao, A Mahipal, J Starr
ESMO Open. 2022-10-01

Lectures

Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

NexImmune Announces Appointment of Dr. Leena Gandhi to Its Board of DirectorsMay 10th, 2022
Bright Peak Therapeutics Appoints Leena Gandhi, M.D., Ph.D., to Its Board of DirectorsFebruary 28th, 2022
Lung Cancer Awareness Month: 2021 Immunotherapy Research UpdatesNovember 1st, 2021
Join now to see all

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member